Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$26.98 USD
-0.56 (-2.03%)
Updated May 20, 2024 04:00 PM ET
After-Market: $26.96 -0.02 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.98 USD
-0.56 (-2.03%)
Updated May 20, 2024 04:00 PM ET
After-Market: $26.96 -0.02 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
B Value D Growth D Momentum C VGM
Zacks News
ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.
Integra (IART) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.
Integra LifeSciences (IART) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 23.21% and 2.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More
by Urmimala Biswas
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
ResMed (RMD) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.
Integra (IART) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.
Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus
by Debanjana Dey
Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.
Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.
Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid
by Zacks Equity Research
Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.
Integra (IART) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Integra (IART) is optimistic about maintaining its strength in its international business, along with its portfolio optimization strategy.
Here's Why You Should Retain Integra LifeSciences (IART) Stock
by Zacks Equity Research
Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.
Integra's (IART) Neurosurgery Rebounds Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,
Veeva (VEEV) Partners With Impel, Boosts Cloud-Based Offerings (Revised)
by Zacks Equity Research
Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.
Integra (IART) Down 3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra (IART) Neurosurgery Grows Sequentially Amid Supply Woe
by Zacks Equity Research
Most of Integra's (IART) franchises or products succeed in sustaining the momentum after returning to growth in the third quarter.
Integra (IART) Arms Grow Sequentially Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.
Integra (IART) Q4 Earnings Top Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.
Integra LifeSciences (IART) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 13.51% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Veeva (VEEV) Partners With Impel, Boosts Cloud-Based Offerings
by Zacks Equity Research
Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.
Integra (IART) Acquires Acell, Focuses on Regenerative Space
by Zacks Equity Research
The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.
Integra (IART) Preliminary Q4 Reported Sales Show Recovery
by Zacks Equity Research
Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.
NEOGEN (NEOG) Fortifies Global Position via Megazyme Buyout
by Zacks Equity Research
NEOGEN's (NEOG) buyout of Megazyme is expected to strengthen its Food Safety business worldwide.